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Background:Mutations in human chymotrypsin C (CTRC) compromise protective trypsinogen degradation and increase
risk for pancreatitis.
Results: CTRC variant p.G214R degraded trypsinogen poorly; was resistant to inhibitors; and cleaved their reactive sites.
Conclusion: Pathogenic variant p.G214R is a functional paralog of mesotrypsin, an inhibitor-degrading trypsin isoform.
Significance: The same mutation that evolved a new function in mesotrypsin causes pathology in the context of CTRC.
Human chymotrypsin C (CTRC) protects against pancreatitis
by degrading trypsinogen and thereby curtailing harmful intra-
pancreatic trypsinogen activation. Loss-of-function mutations
in CTRC increase the risk for chronic pancreatitis. Here we
describe functional analysis of eight previously uncharacterized
natural CTRC variants tested for potential defects in secretion,
proteolytic stability, and catalytic activity. We found that all
variants were secreted from transfected cells normally, and
none suffered proteolytic degradation by trypsin. Five variants
had normal enzymatic activity, whereas variant p.R29Qwas cat-
alytically inactive due to loss of activation by trypsin and variant
p.S239C exhibited impaired activity possibly caused by disulfide
mispairing. Surprisingly, variant p.G214Rhad increased activity
on a small chromogenic peptide substrate but was markedly
defective in cleaving bovine -casein or the natural CTRC sub-
strates human cationic trypsinogen and procarboxypeptidase
A1. Mutation p.G214R is analogous to the evolutionary muta-
tion in humanmesotrypsin, which rendered this trypsin isoform
resistant to proteinaceous inhibitors and conferred its ability to
cleave these inhibitors. Similarly to themesotrypsin phenotype,
CTRC variant p.G214R was inhibited poorly by eglin C, ecotin,
or a CTRC-specific variant of SGPI-2, and it readily cleaved the
reactive-site peptide bonds in eglin C and ecotin. We conclude
that CTRC variants p.R29Q, p.G214R, and p.S239C are risk fac-
tors for chronic pancreatitis. Furthermore, themesotrypsin-like
CTRC variant highlights how the same natural mutation in ho-
mologous pancreatic serine proteases can evolve a new physio-
logical role or lead to pathology, determined by the biological
context of protease function.
Human chymotrypsin C (CTRC)3 is a digestive serine prote-
ase synthesized and secreted by the pancreas as inactive chy-
motrypsinogen C, which becomes activated in the duodenum
by trypsin. CTRC exhibits typical chymotryptic activity and
cleaves after phenylalanine, tyrosine, leucine, and methionine
residues in protein substrates, with higher activity toward leu-
cyl peptide bonds than other chymotrypsins (1–4). Besides its
relatively nonspecific digestive function, human CTRC also
regulates activation of trypsinogens and procarboxypeptidases
through specific cleavages (4–10). Among trypsinogens, the
CTRC-sensitive regulatory nick sites have been best character-
ized in human cationic trypsinogen, the major trypsinogen iso-
form in human pancreatic juice (4–9). Conversion of inactive
trypsinogen to active trypsin is controlled by CTRC via two
independent and seemingly conflicting mechanisms; cleavage
of the trypsinogen activation peptide at the Phe18-Asp19 pep-
tide bond accelerates autoactivation of trypsinogen (5, 7, 8),
whereas cleavage of the Leu81-Glu82 peptide bond in the cal-
ciumbinding loop promotes degradation of trypsinogen (4, 6, 7,
9). In the intestinal milieu, cleavage of the calcium binding loop
is blocked by high calciumconcentrations and trypsinogendeg-
radation is minimal. However, in the presence of submillimolar
calcium concentrations prevailing in pancreatic secretions, the
dominant effect of CTRC is trypsinogen degradation, which is
responsible for protecting the pancreas against premature,
intra-pancreatic activation of trypsinogen. A number of human
genetic studies indicate that loss-of-function mutations in
CTRC increase the risk for chronic pancreatitis (11–15). Simi-
larly, mutations in human cationic trypsinogen that inhibit
CTRC-mediated degradation or accelerate CTRC-mediated
cleavage of the activation peptide cause hereditary chronic
pancreatitis (7). Thus, CTRC is an important failsafe in the pan-
creas against proteolytic enzyme activation, and inborn errors
in this mechanism can result in pancreatic pathology.
CTRC is also a physiological co-activator of procarboxypep-
tidase A1 (CPA1) and A2 (CPA2) in humans (10). These zymo-
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gens possess 94–96-amino acid-long propeptides, which act as
tethered, tight-binding inhibitors of the active enzymes. Tryp-
sin initiates procarboxypeptidase activation by cleaving the
propeptide at its C terminus. The trypsin-cleaved propeptide
stays bound to the enzyme, and only low levels of carboxypep-
tidase activity appear. Full enzyme activity develops after
CTRC-mediated degradation of the propeptide, primarily
driven by cleavage of the Leu96-Leu97 peptide bond (10).
The regulatory functions of CTRC are highly specific, and
other pancreatic chymotrypsins or elastases do not cleave the
CTRC-sensitive nick sites (4, 6, 8). Several studies attempted to
clarify the determinants of this specificity. Phage display-se-
lected variants of the locust-derived chymotrypsin inhibitor
Schistocerca gregaria proteinase inhibitor-2 (SGPI-2) indicated
that negatively charged amino acids on the primed side of the
scissile peptide bond are important for CTRC recognition (16).
This notion seemed in agreement with the natural preponder-
ance of such residues in the regulatory nick sites. However, a
subsequent study in which negatively charged residues around
the Leu81-Glu82 peptide bond in human cationic trypsinogen
weremutated found only small effects on cleavage byCTRC (4).
More recently, the crystal structure of humanCTRCwas solved
in complex with eglin C (see Fig. 1A), and modeling the CTRC
cleavage sites in trypsinogen onto this structure indicated that
long-range electrostatic complementarity determines CTRC
recognition of its regulatory proteolytic sites (17).
Since 2008 when the first CTRC mutations were described
(11), our laboratory has characterized natural variants of CTRC
to identify pathogenic mechanisms that increase pancreatitis
risk (11, 18, 19). In our recent comprehensive study, we ana-
lyzed 32 natural CTRC variants and identified three different
but mutually non-exclusive loss-of-function mechanisms asso-
ciated with pancreatitis: diminished secretion, loss of catalytic
activity, and degradation by trypsin (18). CTRC variants with
reduced secretion also elicited endoplasmic reticulum stress in
pancreatic acinar cells, but the significance of this mechanism
remains indeterminate (18, 19). In the present study, we
extended these findings by functionally analyzing eight previ-
ously uncharacterized CTRC variants, including two novel
variants reported here for the first time. Surprisingly, one of
these variants, p.G214R, turned out to be the functional paralog
of human mesotrypsin, a fascinating trypsin isoform with
unique inhibitor resistance and inhibitor-degrading properties.
Experimental Procedures
Nomenclature—Nucleotide numbering of the coding DNA
forCTRC starts with the first nucleotide of theATG translation
initiation codon. Amino acid residues in human CTRC are
numbered starting with the initiatormethionine of the primary
translation product (chymotrypsinogen C precursor or pre-
chymotrypsinogenC). By convention, eglin C and ecotin amino
acid residues are numbered according to the sequence of the
native, secreted protein (20, 21).
Novel CTRCVariants—AheterozygousCTRC variant c.239GA
(p.R80Q) was found in a human pancreatic cDNA sample from
a de-identified subject of unknown origin and clinical status.
Heterozygous variant c.640GA (p.G214R) was identified in
exon 7 of the CTRC gene in an 18-year-old male referred for
genetic testing because of recurrent acute pancreatitis in Slova-
kia. No other variants were detected in exons 2 and 3 of CTRC
or in the PRSS1 and SPINK1 genes commonly associated with
chronic pancreatitis.
CTRCExpressionPlasmids andMutagenesis—ThepcDNA3.1()
expression plasmids harboring the coding DNA for human
CTRC with or without a His10 affinity tag were constructed
previously (6, 7). CTRC mutants were generated by overlap
extension PCR and ligated into the pcDNA3.1() vector using
XhoI and EcoRI restriction sites. TheHis-tagged versions of the
constructs were used for purifications.
Cell Culture and Transfection—HEK 293T cells were cul-
tured at a density of 1.5  106 cells/well in DMEM supple-
mented with 10% fetal bovine serum, 4 mM glutamine, and 1%
penicillin/streptomycin, at 37 °C, in 6-well tissue culture plates.
Transfections were carried out using 2 g of expression plas-
mid with 5 l of Lipofectamine 2000 (Invitrogen) in 2 ml of
DMEM. After overnight incubation, cells were rinsed and cov-
ered with 2 ml of Opti-MEM. The conditioned Opti-MEM
medium was harvested after 24 or 48 h, as indicated.
Measurement of CTRC Protein Secretion—Aliquots (200 l)
of the conditionedmediumwere precipitated with 10% trichlo-
roacetic acid (final concentration), and the proteins were col-
lected by centrifugation, resuspended in 15l of Laemmli sam-
ple buffer containing 100 mM dithiothreitol, heat-denatured at
95 °C for 5 min, and electrophoresed on 15% SDS-polyacryl-
amide gels. Gels were stained with Coomassie Blue. Densito-
metric quantitation of bands was carried out with the Gel Doc
XR gel documentation system and Image Lab software
(Bio-Rad).
Measurement of CTRC Activity—Aliquots of conditioned
medium (37.5 l) were incubated with 100 nM human cationic
trypsin at 37 °C for 1 h in 0.1 M Tris-HCl (pH 8.0) and 1 mM
CaCl2 in 50-l final volume. CTRC activity was then measured
by adding 150 l of 200 M Suc-Ala-Ala-Pro-Phe-p-nitroani-
lide substrate at 22 °C. Release of the yellow p-nitroaniline was
followed at 405 nm for 1 min in a SpectraMax Plus 384 micro-
plate reader (Molecular Devices), and the rate of substrate
cleavage was determined from the linear portion of the curves.
Expression and Purification of CTRC—His-tagged forms of
CTRC variants were purified from200ml of conditionedmedia
using nickel affinity chromatography, as described previously
(7). Purified CTRC zymogen was activated with 50l of immo-
bilized trypsin (20230, Thermo Scientific) in 3-ml final volume
of 0.1 M Tris-HCl (pH 8.0) for 2 h at 22 °C. Concentration of
active CTRC was determined using active site titration with
ecotin, as described recently (16). The concentration of variants
p.R29Q, p.G214R, p.S239C, and mutant p.G214M was esti-
mated by comparing their protein band intensity with that of
wild-type CTRC on Coomassie Blue-stained gels.
Enzyme Kinetic Analysis—Measurements were performed in
0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20 at
22 °C. CTRC concentration in the assay was 10 nM, with the
exception of variant p.S239C, which was assayed at 40 nM. The
concentration of the Suc-Ala-Ala-Pro-Phe-p-nitroanilide sub-
strate was varied between 5 and 180 M. To determine Km and
kcat, substrate cleavage rates were plotted as a function of sub-
strate concentration and the data points were fitted with the
Mesotrypsin-like CTRC Variant
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Michaelis-Menten hyperbolic equation. To determine the
apparent inhibitory constant (Ki) of chymotrypsin inhibitors
againstvariantp.G214Randmutantp.G214M,kineticmeasure-
ments were performed with 5 nM enzyme in the presence of
increasing inhibitor concentrations (0–2 M). The concentra-
tion of the Suc-Ala-Ala-Pro-Phe-p-nitroanilide substrate was
varied between 5 and 640M. ApparentKm values were plotted
as a function of inhibitor concentration, and apparent Ki was
derived from the negative intercept (Ki) of the linear fit on the
horizontal axis.
Measurement of CPA1 Activity—The assay mixture con-
tained 10 l of CPA1 sample and 70 l of assay buffer (0.1 M
Tris-HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20), and the
reaction was started by adding 20 l of 600 MN-[4-methoxy-
phenylazoformyl]-L-phenylalanine substrate (22). The de-
crease in absorbance was followed at 350 nm for 2min at 22 °C.
Rates of substrate cleavage were calculated from fits to the ini-
tial linear portion of the curves and were expressed in
milliODmin1 units (where OD indicates optical density).
Expression and Purification of Ecotin, Eglin C, and SGPI-
2-C4—Ecotinwas overexpressed inEscherichia coliBL21(DE3)
and purified on a trypsin affinity column (23). The expression
plasmids for eglin C and SGPI-2-C4were kind gifts from Evette
Radisky (Mayo Clinic Cancer Center, Jacksonville Florida) and
Gábor Pál (Eotvos University, Budapest, Hungary), respec-
tively. SGPI-2-C4 is a phage display-selected CTRC-specific
variant of the locust-derived chymotrypsin inhibitor SGPI-2
(16). Purification of these inhibitors followed published proto-
cols (16, 24). Inhibitor concentrations were determined by
titration against active-site titrated bovine trypsin (ecotin) or
wild-type human CTRC (eglin C and SGPI-2-C4).
Equilibrium Binding Assays—Tight-binding inhibition of
wild-type CTRC by eglin C, ecotin, and SGPI-2-C4 was as-
sessed by measuring the apparent dissociation constant (KD)
values in equilibrium, as reported previously (16). CTRC (0.5
nM) and inhibitor (0–1 nM range) were incubated in 0.1 M Tris-
HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20 (final concen-
trations) for 1 h (eglin C, SGPI-2-C4) or 16 h (ecotin) at 22 °C in
black 96-well plates in 200-l volume. Free CTRC concentra-
tions were determined with spectrofluorometry after the
addition of 5 l of 6 mM Suc-Ala-Ala-Pro-Phe-AMC sub-
strate and measuring the rate of substrate cleavage using
excitation and emission wavelengths of 380 and 460 nm,
respectively. Apparent KD values were calculated by plotting
the free CTRC concentration as a function of the total inhibitor
concentration and fitting the data points to the following equa-
tion: yE (E xK((E xK)2 4Ex))/2, where the
independent variable x represents the total inhibitor concen-
tration, the dependent variable y is the free protease concentra-
tion in equilibrium, K is KD, and E designates the total protease
concentration.
Results
CTRC Variants—We studied the functional properties of
eight previously uncharacterized natural CTRC variants (Table
1). Five of these were reported in 2013 by a genetic study from
Japan; variants p.R29Q, p.S239A, p.S239C, and p.K247E were
found in individuals with chronic pancreatitis, whereas variant
p.I209Mwas detected in a control subject (15). Variant p.R80W
was identified during the cDNA cloning of human CTRC,
described then as a “serum calcium decreasing protein,” calde-
crin, by Japanese authors in 1996 (25). Two novel variants were
also included in the present study; variant p.R80Qwas found in
a pancreatic cDNA sample, whereas variant p.G214R was dis-
covered in a subject with chronic pancreatitis in Slovakia.
When positions of the amino acid residues affected by these
variants were examined in the CTRC structure, Arg-80, Gly-
214, and Ser-239 appeared to be in proximity of the bound
substrate-like inhibitor, suggesting that changes at these posi-
tionsmight affect substrate binding and cleavage (Fig. 1A). Fur-
thermore, variant p.R29Q eliminated the activating trypsin
cleavage site; therefore, this change was expected to abolish
activation.
Secretion of CTRC Variants from Transfected Cells—Muta-
tion-induced misfolding may cause intracellular retention and
degradation resulting in diminished secretion of CTRC protein
to the growth medium. We previously observed this loss-of-
function phenotype with several clinically relevant CTRC
variants (18, 19).When secretedCTRCprotein levelsweremea-
sured in the conditioned medium of transiently transfected
HEK 293T cells by SDS-PAGE and densitometry, all eight vari-
ants exhibited levels similar to wild-type CTRC (range
85–125%, Fig. 1, B and C). Thus, none of the studied variants
appeared to undergo significant misfolding, as judged by their
normal secretion.
Activation and Degradation of CTRCZymogens by Trypsin—
The catalytically inactive CTRC precursor is converted to its
active form by trypsin, which cleaves the Arg29-Val30 peptide
bond in the CTRC activation peptide. The cleaved activation
peptide remains attached to CTRC via a disulfide bond (Fig.
1A), but it becomes released under the reducing conditions
utilized during SDS-PAGE, resulting in a small shift in the
migration of active CTRC relative to its zymogen form. When
the eight CTRC variants were treated with trypsin, all exhibited
a small gel shift, with the exception of p.R29Q (not shown).
Resistance to cleavage by trypsin is consistent with the pre-
dicted effect of the p.R29Q variant, which destroys the activat-
ing cleavage site. Normally, trypsin does not cleave CTRC at
any other site; however, mutations may render CTRC proteo-
lytically unstable, and some of the pathogenic CTRC variants
were previously shown to be degraded by trypsin (18). In con-
trast, none of the variants tested here was degraded by trypsin
(not shown).
TABLE 1
CTRC variants studied
Six of the eight variants were previously described in the literature but have not been
functionally characterized. We report here two new CTRC variants. All variants
were found in the heterozygous state in a single individual each, with the exception
of p.K247E, which was detected in three subjects.
CTRC
region
Nucleotide
change
Amino acid
change References
Exon 2 c.86GA p.R29Q 15
Exon 4 c.238CT p.R80W 25
Exon 4 c.239GA p.R80Q This work
Exon 6 c.627CG p.I209M 15
Exon 7 c.640GA p.G214R This work
Exon 7 c.715TG p.S239A 15
Exon 7 c.716CG p.S239C 15
Exon 7 c.739AG p.K247E 15
Mesotrypsin-like CTRC Variant
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Catalytic Activity of CTRC Variants on a Small Peptide
Substrate—After activation with trypsin, enzymatic activity of
CTRC in the conditioned medium was determined with the
small chromogenic peptide substrate Suc-Ala-Ala-Pro-Phe-p-
nitroanilide (Fig. 1B). Activity of CTRC variants p.R80Q,
p.R80W, p.I209M, p.S239A, and p.K247E was comparable with
wild type (range 74–123%). Variant p.R29Q exhibited no
detectable activity, consistent with our observation that this
variant cannot be activated by trypsin.Variant p.S239Cwas also
essentially inactive (3% activity). Remarkably, activity of var-
iant p.G214R was more than three times (328%) higher than
that of wild-type CTRC (Fig. 1B).
To extend these experiments, wild-type CTRC and all vari-
ants were purified from the conditioned medium, and their
enzyme kinetic parameters were determined on the peptide
substrate (Table 2). The catalytic efficiency (kcat/Km) of five
variants was comparable with that of wild-type CTRC within
experimental error. In contrast, variant p.G214R showed a
nearly 2-fold higher specificity constant, which was primarily
due to a 2.7-fold increased kcat value. Because activity measure-
ments in the conditioned medium (Fig. 1B) were carried out
with near saturating substrate concentrations, the elevated kcat
explains the high activity of the p.G214R variant observed
under those conditions. Finally, variant p.R29Qhad nomeasur-
able activity whatsoever, whereas variant p.S239C was catalyt-
ically impaired, with a kcat/Km value that was 56-fold lower than
that of wild type. A possible explanation for the low activity of
variant p.S239C is conformational distortion caused by spuri-
ous disulfides between the newly introduced Cys239 and the
adjacent Cys212 and/or Cys243 residues. This notion remains
speculative, however, as we were unable to demonstrate such
disulfides so far.
Catalytic Activity of CTRCVariants on-Casein—The activ-
ity of all purified CTRC variants was also tested on a larger
protein substrate where the enzyme canmake extended subsite
contacts during substrate binding (Fig. 2). Consistent with the
assays using the peptide substrate, five variants readily cleaved
-casein, whereas variants p.R29Q and p.S239C were inactive
on this protein substrate. Surprisingly, variant p.G214R, which
exhibited exceptionally high activity on the peptide substrate
(Fig. 1B and Table 2), digested -casein poorly (Fig. 2).
FIGURE 1. Expression and activity of CTRC variants. A, ribbon diagram of
the tertiary structure of human CTRC (in green) in complex with eglin C (in
gray) showing the position of CTRC variants (in red) studied in the present
study (Protein Data Bank code 4H4F). Note the cleaved activation peptide,
which remains attached to the active CTRCmolecule through a disulfide link
highlighted in yellow. The C-terminal three amino acids of the activation pep-
tide (Ser27-Ala28-Arg29) are autolytically removed by CTRC and are not pres-
ent in the structure. The image was rendered using PyMOL 1.3 (Schrödinger,
LLC).B, CTRCprotein content andenzymeactivity in the conditionedmedium
of HEK 293T cells transiently transfected with given CTRC variants. Condi-
tionedmediumwas collected 24 h after transfection. CTRC precursor protein
levels (black bars) were determined by SDS-PAGE and densitometry, and
enzyme activity (gray bars) was measured after activation with trypsin using
the Suc-Ala-Ala-Pro-Phe-p-nitroanilide substrate. See “Experimental Proce-
dures” for details. Protein content and activity were expressed relative to
wild-typeCTRCaspercentagevalues (average	S.D.,n3).C, representative
gel stainedwith Coomassie Blue demonstrating secreted CTRCprecursor lev-
els in the conditioned medium of transfected cells.
TABLE 2
Enzyme kinetic parameters of purified CTRC variants and mutants on
the Suc-Ala-Ala-Pro-Phe-p-nitroanilide substrate
Data from three independent experiments were fitted globally to the Michaelis-
Menten hyperbolic equation and the error of the fit is indicated. The p.R29Q variant
had no detectable (ND) activity on this substrate.
Km kcat kcat/Km
M s1 M1s1
Wild type 15.3	 0.6 15.4	 0.1 1.0 106
p.R29Q ND ND ND
p.R80Q 22.6	 0.7 16.5	 0.1 7.3 105
p.R80W 19.4	 0.8 15.1	 0.2 7.8 105
p.I209M 15.7	 0.4 10.3	 0.1 6.6 105
p.G214R 22.1	 1.2 42.2	 0.6 1.9 106
p.S239A 19.0	 0.7 11.7	 0.1 6.2 105
p.S239C 33.1	 4.1 0.6 1.8 104
p.K247E 16.7	 0.9 14.7	 0.2 8.8 105
p.G214A 47.2	 4.2 14.1	 0.4 3.0 105
p.G214M 22.1	 1.2 23.6	 0.3 1.1 106
Mesotrypsin-like CTRC Variant
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Catalytic Activity of CTRC Variants on Human Cationic
Trypsinogen—The protective trypsinogen-degrading activity of
CTRC involves cleavage of the Leu81-Glu82 peptide bond in the
calcium binding loop of cationic trypsinogen, which can be fol-
lowed on SDS-PAGE (Fig. 3A). Similarly to the digestion pat-
tern observed with the -casein substrate, five CTRC variants
cleaved trypsinogen rapidly, whereas variant p.R29Q was inac-
tive and variants p.G214R and p.S239C exhibited diminished
activity.When rates of digestionwere determined by densitom-
etry (Fig. 3B), variants p.G214R and p.S239C cleaved trypsino-
gen at least 30-fold slower than wild-type CTRC.
Activity of Variant p.G214R on Human Procarboxypeptidase
A1—CTRC acts as a co-activator for human procarboxypepti-
dase A1 through catalyzing degradation of the propeptide after
the initial trypsin-mediated cleavage (10). Cleavage of the
CPA1 propeptide by CTRC was monitored by activity assay
(Fig. 4). The CPA1 precursor was first partially activated with
trypsin, and then 5 nM CTRC was added to induce complete
degradation of the propeptide. The increase in CPA1 activity
was followed. Similarly to the cleavage of trypsinogen, variant
p.G214R activated CPA1 at a significantly reduced rate, about
10-fold more slowly than wild-type CTRC.
Variant p.G214R Is Resistant to Tight-binding CTRC
Inhibitors—The catalytic properties of CTRC variant p.G214R
are highly reminiscent of those of human mesotrypsin, an
exceptional trypsin isoform that exhibits increased activity on
small peptide substrates yet cleaves most protein substrates
poorly. Furthermore, mutation p.G214R is analogous to the
evolutionary mutation p.G198R in mesotrypsin, which appears
to be largely responsible for the unique properties of this tryp-
sin isoform. Modeling an Arg side chain at position 214 in the
CTRC structure indicated steric clashwith the P2
 side chain of
the bound eglin C (Fig. 5A), a situation analogous to the effect
of Arg198 in mesotrypsin (26). Because a hallmark feature of
mesotrypsin is its resistance to proteinaceous trypsin inhibi-
tors, we investigated whether CTRC variant p.G214R can be
inhibited by CTRC inhibitors. Three inhibitors were tested:
eglin C, ecotin, and the C4 variant of SGPI-2. The8-kDa eglin
C (MEROPS I13.001) is derived from the medicinal leech (20),
and we previously identified it as a CTRC inhibitor and deter-
mined the structure of its complex with CTRC (17). Ecotin
(MEROPS I11.001) is a pan-serine-protease inhibitor found in
the periplasmic space of E. coli (21, 27). The activemolecule is a
homodimer of two16-kDa subunits, which can bind two pro-
tease molecules. In this heterotetrameric complex, ecotin
inhibits the protease via a primary substrate-like interaction
and a smaller secondary binding site (28). SGPI-2-C4 is a phage
display-selected CTRC-specific variant of the 4-kDa locust-
derived chymotrypsin inhibitor SGPI-2 (an ortholog of MER-
OPS I19.011) (16). Eglin C, ecotin, and SGPI-2-C4 inhibited
human CTRC as tight-binding inhibitors, and we determined
apparent equilibrium dissociation constant (KD) values of 52,
FIGURE 2.Digestion of bovine-casein by human CTRC variants. The digestion reactions contained 0.2mg/ml -casein, 0.1 M Tris-HCl (pH 8.0), 5 nM CTRC,
and 25 nM SPINK1 trypsin inhibitor (final concentrations). The trypsin inhibitor was included to rule out any possible confounding effect of trypsin contami-
nation. Incubationswere performed at 37 °C; at the indicated time points, 100-l aliquotswere precipitatedwith 10% trichloroacetic acid (final concentration)
and analyzed by 15% SDS-PAGE followed by Coomassie Blue staining.
Mesotrypsin-like CTRC Variant
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13, and 47 pM, respectively (Fig. 5B). In contrast to wild-type
CTRC, variant p.G214R was poorly inhibited by these inhibi-
tors, and we were unable to determine an apparent KD in equi-
librium binding assays. Therefore, using a small peptide sub-
strate, Michaelis-Menten parameters were measured in the
presence of increasing inhibitor concentrations, and the Km
values were plotted as a function of the inhibitor concentration.
The slope of the linear fits yielded apparentKi values of 149, 54,
and 224 nM, respectively, indicating that CTRC variant
p.G214R binds proteinaceous inhibitors more than 3 orders of
magnitude weaker relative to wild-type CTRC (Fig. 5C).
Variant p.G214R Cleaves the Reactive-site Peptide Bond of
Inhibitors—Human mesotrypsin cleaves the reactive-site pep-
tide bond of canonical trypsin inhibitors and thereby promotes
their inactivation and further degradation. To test whether
CTRC variant p.G214R also exhibited inhibitor-degrading
activity, eglin C and ecotin were incubated with wild-type and
p.G214R CTRC, and the reactions were analyzed by SDS-
PAGE.Due to its small size, cleavage of SGPI-2-C4 could not be
evaluated by this method. Over the time courses studied, wild-
type CTRC did not cleave eglin C or ecotin to any extent what-
soever, whereas variant p.G214R almost completely cleaved
FIGURE3.Effect of CTRCvariants on the cleavageof the Leu81-Glu82peptidebond inhumancationic trypsinogen. Trypsinogen (Tg, 2M)was incubated
with 20 nM CTRC in 0.1 M Tris-HCl (pH 8.0) in the presence of 25 nM SPINK1 trypsin inhibitor at 37 °C (final concentrations). The trypsin inhibitor was included to
rule out any possible confounding effect of trypsin contamination. A, at the indicated times, aliquots were withdrawn, precipitated with 10% trichloroacetic
acid, and analyzed by reducing SDS-PAGE andCoomassie Blue staining. Representative gels from three experiments are shown. B, densitometric evaluation of
cleavage reactions. Averages of three experiments are shown. For clarity, error bars were omitted; the standard deviation was within 9% of the mean.
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both inhibitors (Fig. 6). As these reactions were performedwith
nearly saturating inhibitor concentrations (4 M), we could
estimate kcat values from the rates of cleavage and obtained
1.3  102 and 7  104 s1 for eglin C and ecotin, respec-
tively. N-terminal protein sequencing by Edman degradation
confirmed that CTRC-mediated cleavage took place at the
Leu45-Asp46 and Met84-Met85 reactive-site peptide bonds in
eglinC and ecotin, respectively (Fig. 6). The results also indicate
that the hydrolysis equilibrium of the reactive-site peptide
bonds in both inhibitors is shifted toward the cleaved form.
Side-chain Bulk Is Responsible for the Mesotrypsin-like Prop-
erties of CTRC Variant p.G214R—Crystal structure of meso-
trypsin harboring the evolutionary p.G198R mutation (32) and
modeling of CTRC variant p.G214R (Fig. 5A) both indicate that
the bulky Arg side chain is responsible for weakened inhibitor
binding and enhanced inhibitor cleavage. To test this notion
experimentally and to assess the possible contribution of the
guanidinium positive charge, we constructed CTRC mutants
p.G214A and p.G214M. When compared with variant
p.G214R, the catalytic properties of mutant p.G214M were
highly similar. Thus, mutant p.G214M cleaved a small peptide
substrate with an increased kcat (Table 2), but it was defective in
cleaving-casein and human cationic trypsinogen (Fig. 7). Fur-
thermore, mutant p.G214M bound eglin C poorly (KD 169 nM)
and rapidly cleaved the reactive-site peptide bond of eglin C
(Fig. 8). In contrast, mutant p.G214A cleaved the small peptide
substrate with an unchanged kcat but with an elevated Km
(Table 2) and digested both -casein and human cationic tryp-
sinogen, although the rate of trypsinogen cleavage was 3.5-fold
slower relative to wild-type CTRC. Interestingly, mutant
p.G214A exhibited inhibitor resistance and bound to eglin C
more than 200-fold weaker than wild-type CTRC, yet at least
20-fold stronger than variant p.G214Rormutant p.G214M.We
note that the measured KD value of 11 nM is a higher estimate
determined after 10 min of incubation when full equilibrium
may not have been reached. The short incubation time was
FIGURE 4. Effect of CTRC variant p.G214R on CPA1 activation. Human
CPA1 zymogen was incubated at 0.2 M concentration with 5 nM human
cationic trypsin at 37 °C in 0.1 M Tris-HCl (pH 8.0) and 0.05% Tween 20 (final
concentrations) in 200-l final volume. After 30 min, 5 nM wild-type or
p.G214R CTRC was added, and CPA1 activity was measured at the indicated
times, as described under “Experimental Procedures.” Average of three
experiments	 S.D. is shown.mOD, milli-optical density units.
FIGURE 5. Inhibition of wild-type CTRC and the p.G214R variant by chy-
motrypsin inhibitors. A, modeling the potential effect of the p.G214R vari-
ant on inhibitor binding. Note that the side chain of Arg214 (in red) sterically
clashes with the P2
 side chain of the bound inhibitor (shown in grayish blue).
The catalytic triad is in yellow. The relevant portion of the human CTRC struc-
ture in complexwith eglin C is shown (Protein Data Bank code 4H4F). B, bind-
ing of inhibitors eglin C, ecotin, and SGPI-2-C4 to wild-type CTRCwas charac-
terized by determining the apparent dissociation constant (KD) values in
equilibriumbinding assays.C, inhibition of variant p.G214R by eglin C, ecotin,
and SGPI-2-C4 was assessed by measuring the apparent competitive inhibi-
tory constants (Ki) in enzyme kinetic experiments. See “Experimental Proce-
dures” for details. Results from three independent experiments were fitted
globally. The data points represent average values	 S.D.
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necessary because in the low inhibitor concentration range
employed, mutant p.G214A slowly inactivated eglin C. How-
ever, when inhibitor cleavage was tested at 4 M eglin C con-
centration, essentially no cleavage was detected during the 2-h
time course studied (Fig. 8), which stands in contrast to the
rapid cleavage observed under these conditions with variant
p.G214R and mutant p.G214M. Taken together, the observa-
tions indicate that side-chain bulk rather than the positive
charge at position 214 is the primary determinant of inhibitor
resistance and cleavage by CTRC variant p.G214R.
Discussion
Loss-of-function CTRC variants increase the risk for chronic
pancreatitis by compromising the protective trypsinogen-de-
grading activity of CTRC in the pancreas. Because most CTRC
variants are rare, genetic analysis cannot determine or rule out
disease association, and classification of clinical significance
must rely on functional analysis (18). Here we characterized
eight CTRC variants, which were not included in our latest
comprehensive study that analyzed 32 CTRC variants (18).
Two of the eight variants, p.R80Q and p.G214R, were reported
here for the first time. Our results identified three CTRC vari-
ants with significant catalytic defects due to unique mecha-
nisms not observed before with other CTRC variants. These
variants, p.R29Q, p.G214R, and p.S239C, are hereby catego-
rized as risk factors for chronic pancreatitis. In agreement with
our assessment, all three variants were identified in patients
with chronic pancreatitis. In contrast, two variants (p.S239A
FIGURE 6. Cleavage of the reactive-site peptide bond in eglin C (A) and ecotin (B) by CTRC variant p.G214R. Inhibitors were incubated at 4 M concen-
tration with wild-type CTRC or the p.G214R variant (100 nM with eglin C and 200 nM with ecotin) in 0.1 M Tris-HCl (pH 8.0), and 1 mM CaCl2 at 37 °C. At the
indicated time points, aliquots (100 l) were precipitated with trichloroacetic acid (10% final concentration) and analyzed by SDS-PAGE and Coomassie Blue
staining. The bandsmarked by asteriskswere subjected to Edman degradation. The N-terminal sequences determined are indicated below the gels. Note that
the cleaved eglin C band contains two co-migrating bands of similar size. Representative experiments from three experiments are shown. The amino acid
sequences of the inhibitors are also shown with the sequenced regions bolded and underlined. Note that in recombinant eglin C, the native N-terminal
sequence of TEF was replaced with MSM and the initiator methionine was removed by methionine aminopeptidase during expression in E. coli.
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and p.K247E) originally identified in subjects with chronic pan-
creatitis were fully functional, indicating that these are not
pathogenic and were only coincidentally found in patients
rather than controls.
Undoubtedly, the most exciting finding of the present study
was variant p.G214R, which exhibited exceptional catalytic
properties. Thus, the variant was highly active on a small pep-
tide substrate, which does not present extensive prime side
contacts for binding, but it exhibited low activity on large pro-
tein substrates such as -casein, human cationic trypsinogen,
or procarboxypeptidase A1. Structural modeling indicated that
the Arg side chain occupied the S2
 subsite and sterically
clashed with the P2
 side chain of substrates and inhibitors. In
agreement with these predictions, CTRC inhibitors eglin C,
ecotin, and SGPI-2-C4 inhibited variant p.G214R with several
thousand-fold diminished affinity relative to wild-type CTRC.
Furthermore, variant p.G214R readily cleaved the reactive-site
peptide bonds in eglin C and ecotin. Taken together, properties
of the p.G214R variant were essentially identical to those of
human mesotrypsin, an inhibitor-resistant trypsin isoform
capable of degrading trypsin inhibitors (26, 29–35). Mesotryp-
sin poorly cleaves most proteins but has high activity on small
chromogenic peptide substrates with limited prime side con-
tacts. Canonical trypsin inhibitors such as bovine pancreatic
trypsin inhibitor (MEROPS I02.001), soybean Kunitz trypsin
inhibitor (MEROPS I03.001), and pancreatic secretory trypsin
inhibitor (MEROPS I01.011) inhibit mesotrypsin with greatly
reduced affinity relative to other human trypsins. Mesotrypsin,
however, efficiently cleaves the reactive-site peptide bond of
these inhibitors, and this function appears to be the most plau-
sible physiological role for this protease. Mesotrypsin consti-
FIGURE 7.Digestion of bovine beta-casein and human cationic trypsino-
gen by CTRCmutants p.G214A and p.G214M. A, digestion of bovine beta-
casein. B, digestion of human cationic trypsinogen (Tg). See Figs. 2 and 3 for
experimental details. Representative gels from three experiments are shown.
C, densitometric evaluation of trypsinogen cleavage reactions. Averages of
three experiments are shown. For clarity, error bars were omitted; the stan-
dard deviation was within 4% of the mean.
FIGURE 8. Inhibition of CTRC mutants p.G214A and p.G214M by eglin C
and cleavage of the reactive-site peptide bond in eglin C. A, binding of
eglin C to mutant p.G214A. See Fig. 5A and “Experimental Procedures” for
details. Note that the incubation time was shortened to 10 min to prevent
inhibitor inactivation. See “Results” for details. B, inhibition of mutant
p.G214MbyeglinCdetermined fromenzymekinetic experiments. See Fig. 5B
and “Experimental Procedures” for details. Results from three independent
experimentswere fitted globally. The data points represent average values	
S.D. C, cleavage of the reactive-site peptide bond in eglin C by CTRCmutants
p.G214A and p.G214M. See Fig. 6 for experimental conditions.
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tutes only a few percent of human trypsins secreted by the pan-
creas (29, 36, 37), which seems to support the idea for such a
highly specialized function. Remarkably, essentially all unique
properties of mesotrypsin are due to an evolutionary mutation
that replaced a Gly residue at position 198 (position 193 in
conventional chymotrypsin numbering) with an Arg. This
mesotrypsin signature mutation p.G198R is analogous to the
p.G214R variant in CTRC; both affect the same conserved Gly
residue. Mutation of Arg198 in mesotrypsin to Gly converts
mesotrypsin to a normal trypsin, demonstrating that this single
evolutionary change is the critical determinant of mesotrypsin
function (31). This notion agreeswith our findings as kcat values
determined for the cleavage of eglin C and ecotin by CTRC
variant p.G214R fall in the same range as turnover numbers
measured for inhibitor cleavage by mesotrypsin (see Table 2 in
Ref. 38). Interestingly, however, recent work from the Radisky
laboratory (39) demonstrated that mesotrypsinmay have accu-
mulated other evolutionary mutations that, to a lesser degree
than Arg198, further reduced binding affinity and increased
cleavage rates toward inhibitors. The unique catalytic proper-
ties of the p.G214R CTRC variant were almost entirely mim-
icked by mutant p.G214M but not by mutant p.G214A,
confirming predictions that side-chain bulk at position 214
is responsible for inhibitor resistance and inhibitor cleavage,
whereas the positive charge of the Arg side chain is
unimportant.
Finally, it is intriguing to observe that the same naturalmuta-
tion in two highly homologous digestive serine proteases has
led to dramatically different biological outcomes: evolutionary
selection of a new physiological function versus pancreatic
pathology. In the case ofmesotrypsin, the newly acquired inhib-
itor-cleaving capability has been advantageous for the organ-
ism, whereas the low digestive activity on protein substrates
was immaterial due to the abundance of other trypsin isoforms.
In contrast, the diminished catalytic activity of CTRC variant
p.G214R toward protein substrates compromised an essential
protective function and resulted in higher disease risk.
Although carriers of the p.G214R CTRC variant may be pro-
tected from dietary chymotrypsin inhibitors that may compro-
mise protein digestion, the harmful pathogenic effect clearly
outweighs this potential digestive benefit.
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